Duke Finds New Way to Kill Cancer During Cell Shifts

Cancer cells have long outsmarted doctors by changing their identity, helping them spread through the body and survive even after treatment seems to work. Now researchers at Duke University School of Medicine have found a crucial moment when these cells let their guard down.

The discovery centers on a brief window when cancer cells shift from one state to another. During these transitions, cancer cells experience something like a computer trying to run too many programs at once. Their genetic material gets tangled and damaged in ways that should kill them.

But cancer cells have a backup plan. They rely on a protein called ATR to repair this damage and complete their transformation safely. Dr. Lee Zou and his team realized this repair process was the weakness they'd been searching for.

In mouse studies, the researchers blocked ATR at precisely the right moment during these cell transitions. The results were striking. Tumors grew more slowly, and the cancer's ability to spread dropped significantly.

The team focused on one particular transition where cancer cells become more mobile and invasive. During this change, they observed harmful tangles forming when RNA stuck to DNA incorrectly. The cells' gene-reading machinery crashed into their DNA-copying machinery, creating even more damage.

Without ATR to fix these problems, cancer cells in transition simply couldn't survive. It's like catching someone mid-leap between two platforms.

The Ripple Effect

This discovery could breathe new life into existing cancer drugs. ATR inhibitors are already being tested in clinical trials, but doctors haven't known the best time to use them. This research suggests timing these drugs to match cell-state transitions could make them far more effective.

Dr. Zou's team is now investigating whether other types of cancer cell transitions show the same temporary weaknesses. If the pattern holds true across different cell changes, it could open multiple new avenues for treatment.

The research emerged from collaboration between Duke, Harvard Medical School, and the Howard Hughes Medical Institute, with funding from the National Institutes of Health, Canadian Institutes of Health, and the Rivkin Center.

For patients who've watched cancer return after treatment seemed successful, this research offers something precious: a new strategy that targets cancer's survival tricks rather than just the cancer cells themselves.